Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330520 | 0.91 | HSD11B1 (0.36) | HSD11B1PTPN11HRH4 | |
| SCHEMBL23331239 | 0.77 | NR1I2 (0.40) | HSD11B1HRH4 | |
| SCHEMBL23330878 | 0.76 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL23330631 | 0.75 | MAPT (0.37) | HRH4 | |
| SCHEMBL23331054 | 0.74 | HSD11B1 (0.43) | HSD11B1GRM2HRH4CNR2 | |
| SCHEMBL23331241 | 0.72 | NR1I2 (0.38) | HSD11B1GRM2CNR2 | |
| SCHEMBL24978006 | 0.72 | HRH4 (0.34) | HRH4 | |
| SCHEMBL23330496 | 0.71 | CNR2 (0.30) | CNR2 | |
| SCHEMBL23330539 | 0.66 | HRH4 (0.33) | PTPN11HRH4 | |
| SCHEMBL24857618 | 0.66 | KDM4E (0.35) | PTPN11HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | HSD11B1 3/4885GRM2 4644/4885PTPN11 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.